Critical Analysis: Sunshine Biopharma (SBFM) & The Competition

Sunshine Biopharma (NASDAQ:SBFM) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Sunshine Biopharma to related companies based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Sunshine Biopharma and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1	1	0	0	1.50
Sunshine Biopharma Competitors	7797	13888	25778	1037	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.65%. Given Sunshine Biopharma’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Sunshine Biopharma has less favorable growth aspects than its rivals.

Profitability

This table compares Sunshine Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-17.94%	-26.36%	-20.60%
Sunshine Biopharma Competitors	-2,380.38%	-217.94%	-15.54%

Volatility and Risk

Sunshine Biopharma has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Sunshine Biopharma’s rivals have a beta of -3.71, meaning that their average stock price is 471% less volatile than the S&P 500.

Institutional and Insider Ownership

42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.7% of Sunshine Biopharma shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Sunshine Biopharma and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Sunshine Biopharma	$36.31 million	-$5.97 million	-0.01
Sunshine Biopharma Competitors	$3.54 billion	$3.18 billion	554.47

Sunshine Biopharma’s rivals have higher revenue and earnings than Sunshine Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Sunshine Biopharma rivals beat Sunshine Biopharma on 9 of the 13 factors compared.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.